Device Technologies has announced the official inclusion of Route 92 Medical’s pioneering FreeClimb® system on the Australian Register of Therapeutic Goods (ARTG) (ARTG 515885, 516066 and 516067), making the innovative neurovascular intervention technology widely accessible across the country.

Device Technologies has been awarded the 2025 Kerrin Rennie Award for excellence in medical technology.

Japan Lifeline Co. Ltd (JLL), a leading Japanese medical device company specialising in cardiology and cardiovascular surgery fields, has taken a significant step in appointing Device Technologies as their exclusive distributor in Australia and New Zealand, as they expand their presence into one of the region’s most significant healthcare markets.

Device Technologies has announced the appointment of Heath Priestly as Chief Executive Officer, succeeding Michael Trevaskis, who will transition to the role of Executive Vice Chairman.

Device Technologies is proud to announce it has been awarded the APAC 2025 Enterprise B2B eCommerce Distributor of the Year for its customer website, Device Online.

Device Technologies has further solidified its commitment to transforming Australian healthcare by welcoming DTect Innovation, a key player in oncology, a field vital to combatting Australia's rising cancer rates.

Device Technologies is delighted to announce that The Hon Ed Husic MP, Minister for Industry and Science, officially opened its National Distribution Centre on March 14, 2024, at Sydney Business Park. This landmark event underscores the ongoing investment in Australian healthcare, demonstrating Device Technologies’ dedication to elevating the sector by ensuring that hospitals across Australia and New Zealand have access to the world’s finest medical technologies.